Truist Securities raises Penumbra stock price target to $312 on strong VTE growth
PositiveFinancial Markets

Truist Securities raises Penumbra stock price target to $312 on strong VTE growth
Truist Securities has raised its price target for Penumbra's stock to $312, reflecting strong growth in the vascular thromboembolism (VTE) market. This adjustment highlights the company's robust performance and potential for future success, making it an exciting time for investors and stakeholders in the healthcare sector.
— via World Pulse Now AI Editorial System





